Enzalutamide Improves Undetectable PSA Levels in Nonmetastatic CSPC
Apalutamide/ADT Confers 100% Recurrence-Free Survival in High-Risk Prostate Cancer
TAR-200 Leads to Lasting Responses in BCG-Unresponsive Bladder Cancer
UGN-102 Produces Comparable Responses Regardless of Surgery in NMIBC Subset